Therapeutics

Kipper Fletez-Brant, a computational biologist with our Therapeutics division, thought he’d be a physicist one day.Growing up in Phoenix, Arizona, Kipper escaped the heat reading “hard-sci-fi novels” with mind-bending plots...

Xin Fang’s interest in science started at the dinner table, listening to her parents talking about what they did each day. Both her mom and dad are plant scientists. Her mom...

23andMe senior scientist in statistical genetics, Suyash Shringarpure, Ph.D. talks about 23andMe's research model and how it offers a surprising opportunity in the study of rare diseases.

A drug to fight cancer will be the first potential therapy to emerge from 23andMe and GlaxoSmithKline collaboration as the two companies announced that the new therapy will begin clinical trials.

23andMe's Head of Therapeutics Kenneth Hillan, M.B., Ch.B., discussed his career and the vision for 23andMe's work in therapeutics

More than 50 23andMe scientists will be participating in the annual meeting of the American Society of Human Genetics in San Diego this year.

23andMe announces the launch of a collaboration with GlaxoSmithKline (GSK) to accelerate our ability to make meaningful discoveries in therapeutics to treat disease.

As part of a series on cutting edge women, The Today Show featured Anne Wojcicki, 23andMe’s CEO and co-founder. The NBC crew followed Anne as she hustled through a typical...

23andMe scientists will be at the annual American Society of Human Genetics meeting in Vancouver this month sharing a wide spectrum of interesting data that includes more on the genetics...

The sobering fact about drug development is that it takes too long and costs too much money. 23andMe wants to change all that. At the annual meeting of the American...